How to Find the Best Dental Practice Broker

Key Takeaways

• A best-in-class dental practice broker delivers diligence-grade EBITDA analysis, competitive buyer processes, clear private-buyer and DSO comparisons, and sell-side-only representation.

• Helpful evaluation criteria can include dental-only specialization, sell-side focus, CPA-led valuations, vetted buyer pools, and transparent fee structures with strong transaction rates.

• McLerran & Associates uses a structured four-stage process (Understand, Create Competition, Find the Right Fit, Maximize Outcome) to help protect seller value.

• CPA-led valuations with documented add-backs and normalized owner compensation can reduce the risk of deals being re-traded during buyer due diligence.

• Discuss your practice, goals, and transition options with McLerran & Associates in a free, confidential discovery call.

How Top Dental Practice Brokers Create Seller Leverage in 2026

1. Dental-only specialization. Confirm the firm works exclusively in dentistry, not across veterinary, ophthalmology, or other verticals. Dental-specific depth shapes buyer relationships, specialty nuance, and valuation accuracy.

2. Sell-side only. The broker should represent you as the seller and never the buyer. Dual representation can create conflicts that quietly cost sellers money.

3. Both transition pathways. A broker who works only doctor-to-doctor or only DSO deals cannot provide a true side-by-side comparison. Confirm they run both paths in meaningful volume.

4. CPA-led, diligence-grade valuation. Ask whether a CPA builds the valuation and documents every add-back. A free or back-of-the-napkin number often becomes the anchor that determines your proceeds and can be re-traded during buyer due diligence.

5. A vetted, competitive buyer pool. Ask how many buyers they actively work with, how they screen out poorly run DSOs, and how many offers a typical listing receives.

6. Verifiable transaction rate. Ask for the firm’s documented close rate and request references from past clients so you can compare performance with broader industry norms.

7. Transparent fee structure and engagement terms. Review exclusivity length, tail-clause scope, and whether the valuation fee is credited at closing. Exclusivity periods beyond six months and tail clauses covering broadly defined “introduced” buyers deserve close scrutiny.

Walk through your practice’s specific situation with McLerran & Associates before you sign an engagement letter.

Typical Dental Practice Broker Fees and What They Cover

Sell-side dental practice brokers typically charge a success fee that can range from 6–12% of final deal value, payable only when the transaction closes. Some firms use a tiered “Double Lehman” scale, such as 10% on the first $1 million of deal value, then lower percentages above that threshold. Upfront valuation fees, when charged, commonly range from $1,500 to $4,000 and are often credited against the final commission.

The more useful question is what the fee actually buys. “Free valuation” firms often use the complimentary appraisal as a lead-generation tool, which can produce a number that does not survive buyer scrutiny. When that number gets challenged in due diligence, the deal can be re-traded downward, sometimes by a large amount.

McLerran & Associates charges a paid, CPA-led valuation fee because the work is diligence-grade from day one. Every add-back is documented, owner compensation is normalized to a market-rate replacement-dentist salary, and the resulting EBITDA figure matches what buyers see when they review the practice. That upfront investment can help reduce the risk of a practice closing at a significantly lower value than initially expected.

How McLerran Structures the Sell-Side Process

Choosing a broker effectively means choosing a process. McLerran & Associates structures every engagement around four stages.

Understand Your Options.

• Identify your “why,” such as reducing administrative burden, taking chips off the table, or planning a full exit.

• Receive a side-by-side valuation that quantifies your practice’s worth in both the private-buyer and DSO markets.

• Review multi-year financial projections across deal structures (cash at close, rollover equity, earnouts) and time horizons of 3, 5, 7, and 10 years.

Create Competition.

• Go to market through a structured, auction-style process rather than a single-buyer negotiation.

• Use a DSO bid process that typically runs 45–60 days and generates around 10 offers per listing.

• Rely on a multiple-buyer solicitation process that can produce final sale values averaging significantly above initial unsolicited offers.

Find the Right Fit.

• Narrow from initial offers to in-person meetings with the top one to three finalists.

• Evaluate each buyer’s clinical-autonomy philosophy, post-close support model, and track record with prior sellers, not just the headline number.

Maximize Your Outcome.

• Negotiate every term of the letter of intent (LOI), including cash at close, equity structure, earnout mechanics, and employment agreement terms.

• Defend the agreed EBITDA through buyer due diligence so the deal does not get re-traded at closing.

What McLerran Handles for Sellers Day to Day

A full-process sell-side engagement covers far more than listing a practice and waiting for offers. McLerran & Associates manages each major stage on the seller’s behalf.

• Valuation. The team remotely accesses practice management software, cross-references financials, and completes a CPA-led EBITDA analysis with every discretionary add-back documented.

• Marketing. They prepare a detailed confidential information memorandum (CIM) and virtual data room that highlight the practice’s strengths for qualified buyers.

• Buyer outreach. For private-buyer deals, outreach can include direct mail, geofencing, study-club relationships, and access to a large premier private-buyer pool. For DSO deals, the firm solicits strategic and financial buyers across a vetted national pool.

• Negotiation. They negotiate the LOI, including valuation, cash at close, equity type (joint-venture level versus holding-company level), and earnout terms, with attention to non-punitive provisions such as pro-rata earnout payouts.

• Diligence defense. The team defends “quality of earnings,” protecting the EBITDA figure when buyer diligence teams probe add-backs, and reminds buyers that other vetted bidders remain available if a re-trade attempt appears.

• Closing advocacy. McLerran plays a quarterback role through closing, including introductions to dental-specific attorneys, lenders, and CPAs.

How McLerran’s Valuation Process Works

The valuation work mentioned above deserves closer examination because it forms the foundation of the entire engagement. McLerran’s CPA-led valuation begins with remote access to the practice’s management software and detailed production reports, then cross-references that data against tax returns and profit-and-loss statements. The team unpacks every discretionary, personal, and non-recurring expense to arrive at true normalized EBITDA.

The methodology differs by pathway. For doctor-to-doctor deals, value can be expressed as a percentage of collections or a multiple of net cash flow, which is the metric individual buyers using SBA financing can underwrite. For DSO and private-equity deals, value is expressed as a multiple of EBITDA after normalizing owner compensation to a market-rate replacement-dentist salary, typically in the range of 25–30% of clinical production for general dentistry. Two dentists selling identical practices can see a significant difference in after-tax proceeds based solely on how the purchase price is allocated and how EBITDA is normalized.

For owners weighing both paths, McLerran delivers a side-by-side valuation that quantifies the practice’s worth in both markets so the decision relies on data rather than guesswork. If an owner is not ready to sell, McLerran updates the valuation at no charge a year later.

Request a side-by-side valuation from McLerran & Associates to see your practice’s potential value in both the private-buyer and DSO markets.

Common Dental Broker Red Flags to Watch For

Sellers who sell once can face a structural disadvantage against buyers who negotiate weekly. These red flags can make that disadvantage more severe.

• Inflated asking prices to secure exclusivity. Valuation pitches significantly above other intermediaries without specific closed-deal comparables can be a disqualifying sign, and a listing that sits on the market often causes collections to erode, which compounds the damage.

• Long exclusivity periods with vague tail clauses. Listing agreements can lock sellers into a minimum 12-month term, with holdover periods extending 1–3 years after expiration. A more balanced tail clause is limited to six months and tied to a named list of buyers the broker actually introduced.

• Weak or unvetted buyer pools. A broker who knows only one or two DSOs cannot create meaningful competitive tension. Ask how many offers a typical listing generates and how poorly run DSOs are screened out.

• Free-valuation lead-generation tactics. A complimentary appraisal usually serves as a lead magnet rather than a defensible number. Aggressive or poorly documented add-backs can damage seller credibility during diligence, and once one add-back is challenged and withdrawn, buyers often re-price the entire transaction.

• Lack of dental-only specialization. Dentists who hire a generic business broker instead of a dental specialist can receive weaker outcomes because generalists may not know which DSOs are actively buying in the seller’s specific geography.

• Undisclosed compensation differences by buyer type. Some brokers receive higher referral fees for DSO transactions than for doctor-to-doctor sales, which can create an incentive to steer sellers toward DSO deals regardless of fit. Ask directly about any such differences.

Broker-Type Comparison

Broker Type	Dental-Only Focus	Both Sale Paths (~50/50)	CPA-Led EBITDA Analysis	Vetted Buyer Pool	Competitive Auction Process	Transaction Rate
DIY / For-Sale-By-Owner	None	No	Buyer-set number	One buyer	None	~15–20%
Local Generalist Broker	Local only; not dental-exclusive	Usually one path	Weak; not CPA-led	1–2 DSOs or small local list	Minimal	Below average
Multi-Vertical Advisor	Spread across healthcare verticals	Sometimes	Variable	Generic; not dental-specific	Some	Variable
“Free Valuation” Firm	Varies	Usually one path	Free / napkin-math; not defensible	Partial list	Low competitive tension	~35–40% industry norm
McLerran & Associates	Dental-only, national, narrow and deep	Yes, private-buyer and DSO, ~50/50	CPA-led, diligence-grade; built to avoid re-trades	Largest premier pool; poorly run DSOs blacklisted	Structured auction; ~10 offers per listing	~85–90%

How McLerran Screens and Vets Buyers

Not every DSO is a good partner for a seller. Some groups entered the market when capital flooded the space after COVID and have since struggled operationally or financially. McLerran & Associates vets buyers the way a cautious investor might vet a stock. The team looks at whether the whole company is profitable and whether revenue is still growing at the offices it already owns. They also review management team experience and stability, along with whether the private-equity sponsor behind the DSO has successfully completed this type of transaction before.

Poorly run DSOs, including those known for creating difficult post-close environments, cutting clinical autonomy, or struggling with capitalization, are blacklisted and never reach McLerran’s sellers. The buyers who do reach the table are pre-qualified on financing certainty, integration capacity, and track record with prior sellers. That vetting makes the competitive auction more meaningful because 10 offers from vetted, well-backed buyers can produce a very different outcome than 10 offers from an unscreened pool.

For private-buyer deals, McLerran maintains a large premier private-buyer pool, with thousands of pre-qualified individual dentists and relationships across study clubs, banks, and dental organizations. This approach means sellers are not limited to whoever happens to respond to a listing website.

McLerran & Associates by the Numbers

McLerran & Associates has guided dental practice owners through transitions for roughly 35 years. The firm’s track record illustrates what a structured, dental-only sell-side process can produce.

• Approximately 2,000 successful practice sales completed

• Approximately $2 billion in closed transaction volume

• More than 10,000 dental practices evaluated, at a pace of roughly 500 per year

• More than 100 years of collective dental-industry experience across a team of former investment bankers, practice-finance lenders, DSO buyers, CPAs, and advisors

• An approximately 85–90% transaction rate among clients

• An average valuation lift of approximately 30% compared to owners selling on their own

• A roughly 50/50 split between private-buyer and DSO transactions, which is relatively rare among advisory firms

Those numbers reflect a repeatable process that includes a defensible valuation, a competitive auction, diligence defense, and sell-side-only representation from first conversation to closed deal. McLerran operates nationally, with offices in Cleveland (led by Justin Klingshim), Atlanta (led by Matt Sutton), Northern Virginia (led by Andrew Kobylski), Los Angeles (led by Steven Au), and Phoenix covering the Mountain West (led by Brian Carroll).

Frequently Asked Questions

Should I sell to a private buyer or a DSO?

The right path can depend on your practice’s size, profitability, and your personal goals. Smaller premier practices, roughly $1 million to $1.5 million in annual revenue, often fit a doctor-to-doctor sale where an individual buyer using SBA financing can underwrite the acquisition. The largest practices, particularly those with multiple providers and strong EBITDA, often point toward the DSO or private-equity path, where institutional buyers may apply higher multiples backed by lower-cost capital.

Owners in the $1.5 million to $3 million revenue range can often go either direction. Because McLerran works both markets in roughly equal measure, the firm can produce a true side-by-side valuation that quantifies your practice’s worth in both the private-buyer and DSO markets. You can then compare estimated after-tax outcomes across deal structures and time horizons before committing to a path, which is something a single-lane broker typically cannot provide.

Why pay for a valuation when other firms offer it free?

A free valuation is typically a lead-generation tool, which means it is a number produced quickly to secure your listing rather than to withstand buyer scrutiny. When a buyer’s quality-of-earnings team examines that number during due diligence, poorly documented add-backs can be challenged and the deal can be re-traded downward. McLerran’s CPA-led valuation is diligence-grade work completed before the practice goes to market. Every add-back is documented, owner compensation is normalized to a market-rate replacement-dentist salary, and the resulting EBITDA figure is the same one buyers see when they review the practice.

In one case, a free valuation placed a practice at $2.5 million. McLerran valued it at $4.5 million, and it sold for $5.25 million after a competitive process. That difference of $2.75 million illustrates how a defensible valuation can influence the final outcome.

How do I know which DSOs are the good ones?

Identifying well-run DSO partners can be one of the most important and most underestimated parts of the sell-side process. As much as 40% of a DSO deal can be paid in equity rather than cash, which means you effectively become an investor in that organization. McLerran vets DSO buyers by examining overall profitability, same-store revenue growth, management team experience, and the track record of the private-equity sponsor behind the platform.

DSOs known for creating difficult post-close environments, reducing clinical autonomy in ways that were not disclosed, or struggling with capitalization are blacklisted and do not reach McLerran’s sellers. The buyers who do reach the table have been pre-qualified, so when you sit down to compare offers, you are choosing among partners with a demonstrated record of treating sellers well, not just the highest headline number.

Next Step: Protect Your Legacy and Practice Value

You built your practice over a career, and the decision of how, when, and to whom to sell it can benefit from the same level of care. A dental-only sell-side advisor that runs a competitive process, defends your valuation through diligence, and helps you find the right fit, whether a private buyer or a DSO partner, can be one of the main factors shaping what you ultimately walk away with.

Discuss your practice, your goals, and your options with McLerran & Associates in a free, confidential consultation. You can also call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com/contact-us.

If you are still deciding whether selling is right for you, consider the McLerran M&A Summit on October 29–30, 2026, a dental-only event designed for owners who have not yet chosen a path. Attendees can join presentations, expert panels, and one-on-one CPA sessions, earn 4 CE credits, and receive a complimentary practice valuation (a $2,500 value). Contact McLerran & Associates to learn more about the Summit and reserve your place.